Modern vaccine against covid-19 is 90 percent effective

As time goes by, the clinical trials of the vaccines against covid-19 are updated little by little and one of them is that of Moderna, which indicated that is 90 percent effective against disease and 95 percent against severe forms of the disease, according to the US biotechnology company announced in the new published results, slightly less than in a previous clinical trial.

The data come from a Phase 3 clinical trial in which more than 30 thousand people in the United States participated. Efficacy is slightly less than the 94.1 percent recorded in a large clinical trial published in the New England Journal of Medicine in December.

Moderna did not say in its statement whether the decrease in efficacy was due to the appearance of new variants, pero the biotech company you are working on two modified versions of your vaccine, specific for the variants, with encouraging results in mice, but which have not yet been peer reviewed.

“New preclinical data on our variant-specific vaccine candidates give us confidence in our ability to anticipate the emergence of new variants,” applauded Moderna chief Stephane Bancel.

As of April 12, Moderna said it had shipped 132 million doses of its covid vaccine worldwide, including 117 million in the United States.

It is still on track to supply an additional 100 million doses to Americans by the end of May, and another 100 million by the end of June.

The company’s clinical trial for adolescents ages 12 to 17 has about 3,000 participants in the United States, and its trial for children ages 6 months to 11 years continues to recruit its 6,750 participants in the United States and China.

Bgpa

–
– .